Table 4 Mortality risk factors after propensity matching cohort

Age (years), median (IQR)

67 (58–79)

63 (48.5)

0.002

Not included ^¶

Male sex, n (%)

84 (52.8)

177 (56.5)

0.442

Comorbidities, n (%)

Diabetes mellitus

44 (27.7)

81 (25.9)

0.676

Hypertension

74 (46.5)

116 (37.1)

0.047

Not included ^¶

Chronic heart disease

47 (26.9)

63 (20.1)

0.022

Not included ^¶

Cerebrovascular disease

21 (13.2)

39 (12.5)

0.818

Chronic obstructive pulmonary disease

17(10.7)

33 (10.5)

0.960

Malignancy

91 (57.2)

153 (48.9)

0.086

Not included ^¶

Charlson comorbidity index score, median (IQR)

6 (4–8)

5 (2–6)

< 0.001

1.18 (1.08–1.28)

Clinical severity at index blood culture time, median (IQR)

SOFA score

7 (4–9)

3 (1–5)

< 0.001

1.33 (1.23–1.44

SIRS

2 (1–3)

2 (1–3)

0.516

ICU support, n (%)

121 (76.1)

106 (33.9)

< 0.001

Not included ^*

Central venous catheter, n (%)

115(72.3)

154 (49.2)

< 0.001

0.79 (0.45–1.38)

Cardiac device, n (%)

10 (6.3)

10 (3.2)

0.115

Prosthetic device, n (%)

6 (3.8)

14 (4.5)

0.722

Site of BSI acquisition, n (%)

Community-acquired

32 (20.1)

122 (39)

< 0.001

1.93 (1.08–3.46)

Nosocomial acquired

127 (79.9)

191 (61)

Source of BSI, n (%)

Primary BSI

66 (41.5)

134 (42.8)

0.786

Secondary BSI

93 (58.5)

179 (57.2)

CR-GN, n (%)

80 (55.9)

59 (20.4)

< 0.001

2.92 (1.72–4.96)

MDR, n (%)

41(25.8)

113 (36.1)

0.024

0.98 (0.58–1.65)

XDR, n (%)

46 (28.9)

30 (9.6)

< 0.001

Not included ^¶

PDR, n (%)

5 (3.1)

4 (1.3)

0.161

FUBC, n (%)

78 (49.1)

158 (50.5)

0.770

FUBC positivity, n (%)

24 (30.8)

33 (20.9)

0.095

1.56 (0.69–3.53)

Persistent BSIs, n (%)

7 (9)

6 (3.8)

0.101

Appropriate empirical antibiotic therapy, n (%)

76 (47.8)

170 (54.3)

0.181